FOSTER CITY, Calif., March 25, 2020 /3BL Media/ – For those with potentially immunosuppressing conditions, such as HIV, the uncertainty caused by the novel coronavirus pandemic can be particularly challenging. Gilead remains focused on ensuring that people living with or at risk for HIV have access to the medications and support needed.
Today, our Week of Service volunteers performed maintenance and landscaping duties with the Boys & Girls Clubs of Oakland. Together, we can help Oakland’s youth grow into future leaders and positive forces in our society. Learn more about their work to support the innovators of tomorrow: http://bit.ly/2IFQoHb.
Funding will Expand Testing, Harm Reduction Services and Healthcare Infrastructure in States with Highest Infection Rates
Harm Reduction Coalition Selected as Lead Grantee to Oversee 5-year Effort to Implement Proven Harm Reduction Strategies in Indiana, Kentucky, North Carolina, Tennessee and West Virginia
Press Release
Funding will Expand Testing, Harm Reduction Services and Healthcare Infrastructure in States with Highest Infection Rates
Harm Reduction Coalition Selected as Lead Grantee to Oversee 5-year Effort to Implement Proven Harm Reduction Strategies in Indiana, Kentucky, North Carolina, Tennessee and West Virginia
While the challenges continue to be daunting, there are numerous signs of progress in the fight to eradicate HIV by 2030.
Between 2012 and 2016, new infections in New York City decreased by 26 percent. In 2017, new infections in San Francisco fell to a record low of 221 in the city that was once known as ground zero for the AIDS epidemic. While we still have a long way to go, each of these headlines would have been unthinkable 24 years ago.
For Kite’s Week of Service, employees spent the day decorating for Halloween with local chapters of Boys & Girls Clubs of America in Santa Monica and Venice, which offer programs to inspire young people to reach their full potential as productive, caring and responsible citizens.
Last week, our Kite employees volunteered at Family Reach, assembling 400 care packages for families affected by cancer.
Family Reach is a non-profit organization that works with 300 hospitals and cancer centers nationwide to support families who are battling cancer through financial aid and education.
FOSTER CITY, Calif., May 2, 2018 /3BL Media/ — Gilead Sciences, Inc. today announced the release of its 2017 Year in Review, composed of its Annual Report and Corporate Social Responsibility report. The Year in Review provides a comprehensive view into the company’s achievements and highlights how it has continued to deliver on its mission to improve the lives of people living with life-threatening diseases.
FOSTER CITY, Calif., November 10, 2017 /3BL Media/ — Gilead Sciences today announced that it has received a top score of 100 percent on the Human Rights Campaign (HRC) 2018 Corporate Equality Index (CEI), a national benchmarking tool on corporate policies and practices related to lesbian, gay, bisexual and transgender (LGBT) employees. Organizations that have earned a 100 percent rating on the CEI have satisfied all criteria for that year and are recognized as a "Best Place to Work for LGBT Equality.”
Funds to support results-driven research and community projects engaged in HIV cure activities
Press Release
FOSTER CITY, Calif., January 11, 2017 /3BL Media/ -- Gilead Sciences, Inc.(Nasdaq:GILD) today announced the recipients of its HIV cure grants program, a fund totaling more than $22 million, which will support 12 new HIV cure research projects.
Gilead Donates $20 Million to Enhance Access to Treatment for Often Fatal Neglected Tropical Disease
Press Release
FOSTER CITY, Calif., September 27, 2016 /3BL Media/ - Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a partnership with the World Health Organization (WHO) to provide $20 million in funding and drug donations over five years to expand access to diagnostic services and treatment for visceral leishmaniasis (VL). As part of this collaboration, Gilead will donate 380,000 vials of AmBisome® (amphotericin B liposome for injection) to meet the needs of WHO to treat VL in key endemic countries, including Bangladesh, Ethiopia, India, Nepal, South Sudan and Sudan.
